Biologics and Drug‐Induced Immunogenicity: A Case Report of Acquired Hemophilia A Presenting After Immunotherapy

Read full text
Authors: Kevin A. Murgas, Sundus Nasim, Stephen Poos, Jules A. Cohen, Anna Andrzejczyk
Cited by: 1
References: 31

Abstract

Acquired hemophilia A is a rare, potentially life-threatening bleeding disorder caused by autoantibody inhibitors to coagulation factor VIII. We report the case of an 87-year-old female who presented with symptomatic bleeding and was subsequently diagnosed with acquired hemophilia A. Her clinical course, treatment, and recovery are described. Notably, her recent medication history included ixekizumab, an immunotherapy agent used for an underlying autoimmune condition, and a course of antibiotics, complicating the identification of a definitive etiology. This case raises the possibility of ixekizumab as a potential novel pharmacologic trigger for AHA. We highlight challenges in establishing causality and review current literature on hematologic manifestations of drug-induced autoimmunity, with a focus on biologic immunotherapies.

Fields of Study & Subjects

Hemophilia Treatment and Research Platelet Disorders and Treatments Complement system in diseases

Publication details

Journal / source
Clinical Case Reports
Publisher
Wiley
Volume
14
Issue
5
Pages
e72727–e72727
Publication date
1 May 2026
Language
EN